ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 98 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $420,734 | -42.9% | 87,653 | -10.6% | 0.00% | – |
| Q2 2023 | $736,461 | +166144.0% | 98,064 | 0.0% | 0.00% | – |
| Q1 2023 | $443 | -62.6% | 98,064 | -6.7% | 0.00% | – |
| Q4 2022 | $1,184 | -99.9% | 105,065 | -9.1% | 0.00% | – |
| Q3 2022 | $1,107,000 | +17.1% | 115,621 | -1.0% | 0.00% | – |
| Q2 2022 | $945,000 | +8.4% | 116,819 | +140.2% | 0.00% | – |
| Q1 2022 | $872,000 | -36.4% | 48,626 | -23.9% | 0.00% | – |
| Q4 2021 | $1,372,000 | -71.5% | 63,856 | -2.0% | 0.00% | -100.0% |
| Q3 2021 | $4,814,000 | -7.3% | 65,185 | -31.3% | 0.00% | -50.0% |
| Q2 2021 | $5,191,000 | -18.7% | 94,937 | +9.7% | 0.00% | 0.0% |
| Q1 2021 | $6,385,000 | +57.9% | 86,578 | +84.6% | 0.00% | +100.0% |
| Q4 2020 | $4,043,000 | +198.2% | 46,905 | +30.6% | 0.00% | 0.0% |
| Q3 2020 | $1,356,000 | – | 35,908 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $46,559,640 | 13.20% |
| Vivo Capital, LLC | 4,220,048 | $20,256,230 | 2.22% |
| Logos Global Management LP | 1,000,000 | $4,800,000 | 0.64% |
| Orbimed Advisors | 2,871,000 | $13,780,800 | 0.29% |
| Redmile Group, LLC | 1,283,289 | $6,159,787 | 0.29% |
| BRAIDWELL LP | 1,249,900 | $5,999,520 | 0.19% |
| Cormorant Asset Management, LP | 612,079 | $2,937,979 | 0.17% |
| Nan Fung Group Holdings Ltd | 41,950 | $201,360 | 0.16% |
| Forefront Analytics, LLC | 13,769 | $66,092 | 0.04% |
| CORNERCAP INVESTMENT COUNSEL INC | 35,071 | $168,341 | 0.03% |